Ku­ra spells out piv­otal AML tri­al win as it gears up to com­pete with Syn­dax

Ku­ra On­col­o­gy said one-quar­ter of pa­tients with cer­tain forms of ad­vanced acute myeloid leukemia went in­to com­plete re­mis­sion af­ter re­ceiv­ing its tar­get­ed ther­a­py.

In 112 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER